Skip to Content
Top

BY Ron Gilmore

A phase two study investigating the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective front-line treatment for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.

Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast...

BY MD Anderson staff

By reducing investments in medical research, any short-term savings will prove to be very costly in the long run — and not just financially...

BY Ron Gilmore

A study investigating the potential of the antifibrotic compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in...

BY Ron Gilmore

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it’s among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

Researchers behind a study at MD Anderson Cancer Center believe they may have found a molecule-based approach to halting 3q26.2’s destructive nature. By manipulating a noncoding microRNA (miRNA) known as miR569 that is part of the amplicon, scientists...

BY Bryan Tutt

Although primary uveal melanoma can be effectively treated with radiation or surgery, patients with metastatic disease — or those at high...

BY Scott Merville

Biotech companies Intrexon and ZIOPHARM Oncology have licensed unique MD Anderson immunotherapy technology, creating an...